Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Amarantus Bioscience Holdings, Inc. (OTC: AMBS).

Full DD Report for AMBS

You must become a subscriber to view this report.


Recent News from (OTC: AMBS)

Biogen slump pressures other biotechs
Biogen's ( BIIB -8.9% ) post-BAN2401 data-stoked drop appears to be affecting some of the other Alzheimer's players. More news on: Biogen Inc., SPDR Biotech ETF, Eisai Co., Ltd. ADR, Healthcare stocks news, Stocks on the move, News on ETFs, Read more ...
Source: SeekingAlpha
Date: July, 26 2018 10:32
Amarantus updates on subsidiaries
Amarantus Bioscience Holdings ( OTCPK:AMBS ) updates investors on key activities in its subsidiaries: More news on: Amarantus Bioscience Holdings, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: July, 20 2018 08:44
Amarantus Provides Corporate Update
NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies a...
Source: GlobeNewswire
Date: July, 20 2018 08:17
MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development advancing the orphan-drug designated therapeutic protein mesencephalic astrocyte-derived n...
Source: GlobeNewswire
Date: July, 09 2018 08:00
MANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal Model
NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development advancing the orphan-drug designated therapeutic protein mesencephalic astrocyte-derived neurotro...
Source: GlobeNewswire
Date: June, 11 2018 07:00
Amarantus Provides Update on Elto Pharma Capital Formation Plan
NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire –   Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and opht...
Source: GlobeNewswire
Date: June, 07 2018 09:08
MANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science Advances
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- MANF Therapeutics, Inc. , a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development advancing the orphan-drug designated therapeutic protein mesencephalic astrocyte-derived neurot...
Source: GlobeNewswire
Date: June, 05 2018 08:11
Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"
Scope of exercised Exclusive Option Agreement expanded to include negotiations for IP rights to additional key markers collected in German clinical study, including CSF-tau NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS)...
Source: GlobeNewswire
Date: May, 30 2018 08:00
Amarantus to Present at LD Micro and The Reg A Conference
NEW YORK, May 24, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and ...
Source: GlobeNewswire
Date: May, 24 2018 11:00
Amarantus Retains Weild & Co. to Advise on JOBS Act Funding
Mr. Heng Fai Chan converts secured debt into common equity NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-cl...
Source: GlobeNewswire
Date: May, 22 2018 06:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.019250.021680.02260.01925183,955
2018-12-130.01960.01950.02160.0195124,065
2018-12-120.020.020350.02150.0195187,506
2018-12-110.0180.020150.02080.018112,207
2018-12-100.02010.019990.02470.01961,288,511

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14143,476183,95577.9952Short
2018-12-1368,820124,06555.4709Short
2018-12-1210,500187,5065.5998Cover
2018-12-11106,907112,20795.2766Short
2018-12-10548,2771,088,51150.3694Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AMBS.


About Amarantus Bioscience Holdings, Inc. (OTC: AMBS)

Logo for Amarantus Bioscience Holdings, Inc. (OTC: AMBS)

Amarantus Bioscience Holdings AMBS is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS wholly owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase b ready small molecule indicated for Parkinson s disease levodopa induced dyskinesia, Alzheimer s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program ESS , a regenerative medicine based approach for treating severe burns with full thickness autologous skin grown in tissue culture that is being pursued by AMBS wholly owned subsidiary Cutanogen Corporation. AMBS wholly owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte derived neurotrophic factor MANF . MANF Therapeutics, Inc. is developing MANF based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS proprietary discovery engine PhenoGuard. AMBS also owns approximately . million shares of Avant Diagnostics, Inc. via the sale of its wholly owned subsidiary Amarantus Diagnostics, Inc. that occurred in May .

 

 

 

Current Management

  • Gerald E. Commissiong / CEO, President, COO
  • John W. Commissiong / CSO
  • Gerald E. Commissiong /
  • John W. Commissiong /
  • Robert L. Harris / Independent Director
  • Donald D. Huffman / Independent Director
  • Steve Spence / Independent Director
  • Steven Spence / Independent Director

Current Share Structure

  • Market Cap: $7,459,696 - 03/20/2018
  • Authorized: 250,000,000 - 03/01/2018
  • Issue and Outstanding: 135,630,841 - 03/01/2018
  • Float: 75,956,228 - 12/06/2017

 


Recent Filings from (OTC: AMBS)

Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current Information
Filing Type: Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current InformFiling Source: OTC Markets
Filing Date: December, 08 2017
Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current Information
Filing Type: Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current InformFiling Source: OTC Markets
Filing Date: December, 08 2017
Quarterly Report - OTC Pink Disclosure Guidelines Q3-2017
Filing Type: Quarterly Report - OTC Pink Disclosure Guidelines Q3-2017Filing Source: OTC Markets
Filing Date: December, 07 2017
Annual Report - OTC Pink Disclosure Guidelines
Filing Type: Annual Report - OTC Pink Disclosure GuidelinesFiling Source: OTC Markets
Filing Date: December, 07 2017
Quarterly Report - Amarantus 2017 Q1-Q3 2017
Filing Type: Quarterly Report - Amarantus 2017 Q1-Q3 2017Filing Source: OTC Markets
Filing Date: December, 07 2017
Annual Report - Amarantus 2016 Fiscal Year 2016
Filing Type: Annual Report - Amarantus 2016 Fiscal Year 2016Filing Source: OTC Markets
Filing Date: December, 07 2017
Certification of termination of registration of a class of security under Section 12(g) or notice of suspension of duty to file reports under Section 13 and 15(d) of the Act Section 12 (g).
Filing Type: 15-12GFiling Source: edgar
Filing Date: December, 04 2017

 

 


Daily Technical Chart for (OTC: AMBS)

Daily Technical Chart for (OTC: AMBS)


Stay tuned for daily updates and more on (OTC: AMBS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AMBS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AMBS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AMBS and does not buy, sell, or trade any shares of AMBS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/